Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT00983528 is registered in ClinicalTrials.gov with University of California, San Diego as lead sponsor.

NCT NCT00983528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00983528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
Lead sponsor
University of California, San Diego
Phase
Phase 1/2
Overall status
Terminated
Start date
September 30, 2009
Completion date
September 30, 2011
Enrollment
6 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia